NextCure, Inc. (NXTC)

NextCure, Inc. is trading at $6.56, down 14.92% on the session. The 50 day average sits at $3.84 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 70.7, which reads as overbought, and MACD is bullish crossover. Volume is below average.

The nearest support is around $4.01 with resistance near $9.90, so that band frames the current range. Average daily movement is roughly $1.00, or about 15.2% of the share price, which is what any stop placement has to allow for. The overall health score of 54 out of 100 combines a trend score of 64, momentum of 78 and a risk score of 4.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.